31-valent pneumococcal conjugate vaccine

Phase 3

31-valent pneumococcal conjugate vaccine is one of 3 therapeutic programs targeting Pneumococcal Vaccines. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Pneumococcal VaccinesActive, not recruiting

Pneumococcal VaccinesPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Pneumococcal Vaccines

#DrugCompanyPhaseTrials

Seasonal Influenza Vaccine

Novartis

Phase 3

1 2

PCV20

Merck & Co.

Phase 3

1 3

31-valent pneumococcal conjugate vaccine

VVaxcyte, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Pneumococcal Vaccines

NCT07365826

Phase 3Active, not recruiting

Pneumococcal Vaccines

NCT07425392

Clinical

Trials by Indication[1]

Pneumococcal Vaccines2 trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older

Active, not recruiting·VVaxcyte, Inc.·Phase 3·NCT07365826·1,390 enrolled

A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination

Active, not recruiting·VVaxcyte, Inc.·Phase 3·NCT07425392·752 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for 31-valent pneumococcal conjugate vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for 31-valent pneumococcal conjugate vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Vaxcyte, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: VVaxcyte, Inc.

31-valent pneumococcal conjugate vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Pneumococcal Vaccines2 trials

References

Drug Info

Quick Facts

Related News